Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
Clinical Pearls:
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen